# Product Snapshot - JPMorgan Funds - Thematics - Genetic Therapies > Audience: country=gb, language=en, role=adv. > Generated: 2026-11-15T21:02:04.863560739Z. ## Identity - **Fund Name**: JPMorgan Funds - Thematics - Genetic Therapies - **Share Class Name**: JPM Thematics - Genetic Therapies A (acc) - USD - **Product Page**: [Product Page](https://am.jpmorgan.com/gb/en/asset-management/adv/products/jpm-thematics-genetic-therapies-a-acc-usd-lu2050612402) - **ISIN**: LU2050612402 - **Fund Type**: SICAV - **Asset Class**: Equity ## OVERVIEW ### Investment objective To achieve a return by investing in companies with exposure to the theme of genetic therapies, globally. ### Registered countries - **Austria**: 22/10/2019 - **Belgium**: 22/10/2019 - **Chile**: 21/10/2020 - **Cyprus**: 13/11/2025 - **Denmark**: 05/11/2019 - **Finland**: 05/11/2019 - **France**: 22/10/2019 - **Germany**: 22/10/2019 - **Greece**: 22/10/2019 - **Hungary**: 18/03/2020 - **Italy**: 06/11/2019 - **Liechtenstein**: 07/07/2020 - **Luxembourg**: 16/10/2019 - **Netherlands**: 22/10/2019 - **Norway**: 05/11/2019 - **Portugal**: 06/12/2023 - **Spain**: 22/10/2019 - **Sweden**: 05/11/2019 - **Switzerland**: 18/10/2019 - **Taiwan**: 26/05/2021 - **United Kingdom**: 17/10/2019 ## Fund facts - **Bloomberg**: JPGTAUA LX - **Reuters**: LU2050612402.LUF - **ISIN**: LU2050612402 - **SEDOL**: BHWTR80 - **Asset class**: Equity - **Region**: Global - **Fund inception date**: 24/10/2019 - **Share class inception**: 24/10/2019 - **Fund currency**: USD - **Share class currency**: USD - **ESG Approach**: Thematic [Disclosure 1] - **SFDR Classification**: Article 8 [Disclosure 2] ## Fund stats - **NAV As of 13/11/2026**: USD 126.46 [Disclosure 3] - **NAV change As of 13/11/2026**: USD -1.88 - **NAV change (%) As of 13/11/2026**: -1.46% - **12 Month NAV high As of 26/08/2026**: USD 138.75 - **12 Month NAV low As of 18/11/2025**: USD 103.94 - **Fund size As of 13/11/2026**: USD 368.27 Mn ## Fees ### Fees - **Initial charge**: 5.00% - **Redemption charge**: 0.00% - **Ongoing charge**: 1.02% - **Annual management fee (included in ongoing charge)**: 0.72% - **Operating & administrative expenses (included in ongoing charge)**: 0.30% ## Portfolio managers ### Yazann Romahi - **Biography**: [Biography](https://am.jpmorgan.com/gb/en/asset-management/adv/bios/yazann-romahi/) - **In the industry**: 27 YEARS - **With J.P. Morgan**: 23 YEARS - **Managing this fund**: 7 YEARS ### Aijaz Hussain - **Biography**: [Biography](https://am.jpmorgan.com/gb/en/asset-management/adv/bios/aijaz-hussain/) - **In the industry**: 11 YEARS - **With J.P. Morgan**: 10 YEARS - **Managing this fund**: 7 YEARS ## Performance ### Quarterly rolling 12 months _As of 30/09/2026_ | Return | 2021/2022 | 2022/2023 | 2023/2024 | 2024/2025 | 2025/2026 | | --- | ---: | ---: | ---: | ---: | ---: | | JPM A (acc) - USD | -34.84% | -12.19% | 7.69% | -1.82% | 35.30% | | Benchmark | -20.66% | 20.80% | 31.76% | 17.27% | 16.75% | | Excess return (geometric) | -17.87% | -27.31% | -18.26% | -16.28% | 15.89% | ### Calendar year _As of 31/10/2026_ | Return | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | YTD | | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | JPM A (acc) - USD | - | - | - | - | 45.74% | -12.76% | -29.55% | -3.47% | -11.69% | 24.30% | 20.28% | | Benchmark | - | - | - | - | 16.25% | 18.54% | -18.36% | 22.20% | 17.49% | 22.34% | 11.18% | | Excess return (geometric) | - | - | - | - | 25.36% | -26.40% | -13.70% | -21.01% | -24.84% | 1.60% | 8.19% | ### Cumulative _As of 31/10/2026_ | Return | 1 MONTH | 3 MONTHS | 1 YEAR | 3 YEARS | 5 YEARS | SINCE INCEPTION | | --- | ---: | ---: | ---: | ---: | ---: | ---: | | JPM A (acc) - USD | -0.01% | 11.95% | 26.93% | 61.76% | -15.10% | 34.81% | | Benchmark | -1.64% | -0.14% | 12.33% | 82.93% | 61.80% | 134.80% | | Excess return (geometric) | 1.65% | 12.11% | 13.00% | -11.58% | -47.53% | -42.58% | ### Annualised _As of 31/10/2026_ | Return | 3 YEARS | 5 YEARS | SINCE INCEPTION | | --- | ---: | ---: | ---: | | JPM A (acc) - USD | 17.39% | -3.22% | 4.35% | | Benchmark | 22.30% | 10.10% | 12.93% | | Excess return (geometric) | -4.02% | -12.10% | -7.60% | [Disclosure 4] ## Portfolio ### Top holdings _As of 30/09/2026_ | Name | Sector | Weight | | --- | ---: | ---: | | Twist Bioscience | Health Care | 4.5% | | Iovance Biotherapeutics | Health Care | 3.6% | | WuXi AppTec | Health Care | 3.5% | | Charles River Laboratories | Health Care | 3.2% | | Amgen | Health Care | 3.1% | | Biogen | Health Care | 3.1% | | Gilead Sciences | Health Care | 3.1% | | Krystal Biotech | Health Care | 2.9% | | Bristol-Myers Squibb | Health Care | 2.9% | | Johnson & Johnson | Health Care | 2.7% | ### Regional breakdown _As of 31/10/2026_ | Region | Fund | Benchmark | Deviation | | --- | ---: | ---: | ---: | | North America | 70.9% | 67.7% | 3.2% | | Europe & Middle East ex UK | 13.8% | 10.7% | 3.1% | | Emerging Markets | 6.9% | 11.2% | -4.3% | | Japan | 5.1% | 5.1% | 0.0% | | United Kingdom | 1.4% | 3.1% | -1.7% | | Pacific ex-Japan | 1.4% | 2.2% | -0.8% | | Cash | 0.5% | 0.0% | 0.5% | | Total | 100.0% | 100.0% | 0.0% | ## COMMENTARY **As of **: 31/10/2026 ### Month in review The JPM Genetic Therapies A (acc) USD share class’ performance was flat in October, outperforming the MSCI ACWI Index by 1.7%. The broader biotechnology sector’s performance was positive; the MSCI ACWI Biotechnology Index returned +8.8%, while the MSCI ACWI Biotechnology Small Cap Index returned +0.5% over the month. Top performing stocks included Charles River Laboratories, which rose following the company announcing a partnership with Magellan Stem Cells to provide viral-safety testing using next-generation sequencing for Zelestrocel, Magellan’s off-the-shelf stem-cell therapy for osteoarthritis, as it prepares to enter Phase III. During Gilead Science’s successful Q3 2026 earnings call, management highlighted the upcoming FDA approval decision date for anito-cel, an anti-BCMA CAR-T therapy acquired via the company’s earlier purchase of Arcellx. The company outlined its commercial launch goals, aiming for 80% Authorized Treatment Centre (ATC) activation within six months and 90% payer coverage within a year of potential approval. Regeneron Pharmaceuticals released positive follow-up data for its first-of-its-kind in vivo gene therapy for genetic hearing loss linked to OTOF variants, which received accelerated FDA approval earlier in the year. The new data shows lasting improvements in hearing. Bottom performing stocks included Iovance Biotherapeutics, which fell following mixed clinical trial results for its cell therapy in advanced lung cancer, with efficacy concentrated in a narrower patient subgroup, raising concerns around the therapy’s broader commercial opportunity. Twist Bioscience declined due to heavy profit-taking after an aggressive multi-hundred-percent rally, an earnings EPS miss and a broader market rotation away from richly valued AI-linked growth equities. Alnylam Pharmaceuticals detracted after its third-quarter update, as management highlighted slower-than-expected demand growth for AMVUTTRA, its key treatment for ATTR amyloidosis, raising concerns about the pace of new patient starts. ### Looking ahead We believe the worst of the biotechnology sector drawdown is likely behind us. Early signs of recovery are emerging, supported by a strong approvals pipeline and a more constructive global regulatory backdrop. In the US, the FDA’s late-2025 guidance on cell & gene therapy approvals – including a roadmap that, for the first time, outlines a potential approval path for personalised gene-editing therapies – should continue to allow for greater flexibility by removing some of the more stringent data requirements. The gene & cell therapy clinical-trial pipeline continues to broaden across all stages. The 2027 approvals outlook appears healthy. Acquisition activity remains steady and early-stage funding has picked up relative to last year. The deep development pipeline and reduced regulatory hurdles could together catalyse a period of growth for the sector. ## Documents - [Factsheet](https://jp.techrules.com/rebrandingPDF/LoadPdf.aspx?ShareClassId=13996&country=GB&lang=EN¶mMIFID=YES) - [JPMorgan Funds - Thematics - Genetic Therapies - Commentary (A Acc share class)](https://am.jpmorgan.com/content/dam/jpm-am-aem/emea/regional/en/literature/commentary/jpm-thematics-genetic-therapies-commentary-ce-en.pdf) - [Key Investor Information Document](https://wl.fundsquare.net/serv/down-doc/request?cdClient=jpmorgan&isin=LU2050612402&docTypeCode=KIID&docLang=EN&docCountry=GB) - [JPMorgan Funds - Prospectus](https://am.jpmorgan.com/content/dam/jpm-am-aem/emea/regional/en/regulatory/prospectus/jpmorgan-funds-prospectus-ce-en.pdf) - [JPMorgan Funds - Annual Report](https://am.jpmorgan.com/content/dam/jpm-am-aem/emea/regional/en/regulatory/annual-report/jpmorgan-funds-annual-report-ce-en.pdf) - [JPMorgan Funds - Semi-Annual Report ](https://am.jpmorgan.com/content/dam/jpm-am-aem/emea/regional/en/regulatory/semi-annual-report/jpmorgan-funds-semi-annual-report-ce-en.pdf) ## Disclosures 1. Investments in themes or assets specifically related to sustainability. 2. "Article 8” strategies promote social and/or environmental characteristics, but do not have sustainable investing as a core objective. “Article 9” strategies have a sustainable investment objective. 3. Net Asset Value of a fund’s assets less its liabilities per Share. 4. Past performance is not a guide to current and future performance. The value of your investments and any income from them may fall as well as rise and you may not get back the full amount you invested. Source: J.P. Morgan Asset Management. Share class performance is shown based on the NAV (net asset value) of the share class with income (gross) reinvested including actual ongoing charges excluding any entry and exit fees. Benchmark Source: MSCI. Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved, in or related to compiling, computing, or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI's express written consent. The return of your investment may change as a result of currency fluctuations if your investment is made in a currency other than that used in the past performance calculation. Indices do not include fees or operating expenses and you cannot invest in them. The benchmark is for comparative purposes only unless specifically referenced in the Sub-Funds' Investment Objective and Policy.